These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 36583804)

  • 1. Sarcopenia Defined by Psoas Muscle Thickness Predicts Mortality After Transjugular Intrahepatic Portosystemic Shunt.
    Li T; Liu J; Zhao J; Bai Y; Huang S; Yang C; Wang Y; Zhou C; Wang C; Ju S; Chen Y; Yao W; Xiong B
    Dig Dis Sci; 2023 Apr; 68(4):1641-1652. PubMed ID: 36583804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarcopenia in Patients with Cirrhosis after Transjugular Intrahepatic Portosystemic Shunt Placement.
    Liu J; Ma J; Yang C; Chen M; Shi Q; Zhou C; Huang S; Chen Y; Wang Y; Li T; Xiong B
    Radiology; 2022 Jun; 303(3):711-719. PubMed ID: 35289658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of nutritional status on the outcome of transjugular intrahepatic portosystemic shunt in patients with cirrhosis: a systematic review.
    Giri S; Anirvan P; Chaudhary M; Tripathy T; Patel RK; Rath MM; Panigrahi MK
    Br J Radiol; 2024 Feb; 97(1154):331-340. PubMed ID: 38276881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sarcopenia Is Associated With Development of Acute-on-Chronic Liver Failure in Decompensated Liver Cirrhosis Receiving Transjugular Intrahepatic Portosystemic Shunt.
    Praktiknjo M; Clees C; Pigliacelli A; Fischer S; Jansen C; Lehmann J; Pohlmann A; Lattanzi B; Krabbe VK; Strassburg CP; Arroyo V; Merli M; Meyer C; Trebicka J
    Clin Transl Gastroenterol; 2019 Apr; 10(4):e00025. PubMed ID: 30939488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sarcopenia Does Not Worsen Survival in Patients With Cirrhosis Undergoing Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites.
    Benmassaoud A; Roccarina D; Arico F; Leandro G; Yu B; Cheng F; Yu D; Patch D; Tsochatzis E
    Am J Gastroenterol; 2020 Nov; 115(11):1911-1914. PubMed ID: 33156111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent.
    Tsien C; Shah SN; McCullough AJ; Dasarathy S
    Eur J Gastroenterol Hepatol; 2013 Jan; 25(1):85-93. PubMed ID: 23011041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of Patient Survival with Psoas Muscle Density Following Transjugular Intrahepatic Portosystemic Shunts: A Retrospective Cohort Study.
    Zhang B; Cai W; Gao F; Lin X; Qian T; Gu K; Song B; Chen T
    Med Sci Monit; 2022 Jan; 28():e934057. PubMed ID: 35031594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sarcopenia is an independent risk factor for short-term mortality in patients undergoing transjugular intrahepatic portosystemic shunt.
    Stoffel E; Hwang SY; Qian X; Geller B; Morelli G; Zhang W
    Eur J Gastroenterol Hepatol; 2024 Aug; 36(8):1010-1015. PubMed ID: 38808872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contributory roles of sarcopenia and myosteatosis in development of overt hepatic encephalopathy and mortality after transjugular intrahepatic portosystemic shunt.
    Yin L; Chu SL; Lv WF; Zhou CZ; Liu KC; Zhu YJ; Zhang WY; Wang CX; Zhang YH; Lu D; Cheng DL
    World J Gastroenterol; 2023 May; 29(18):2875-2887. PubMed ID: 37274064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poor performance of psoas muscle index for identification of patients with higher waitlist mortality risk in cirrhosis.
    Ebadi M; Wang CW; Lai JC; Dasarathy S; Kappus MR; Dunn MA; Carey EJ; Montano-Loza AJ;
    J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1053-1062. PubMed ID: 30269421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increase of radiologically determined muscle area in patients with liver cirrhosis after transjugular intrahepatic portosystemic shunt.
    March C; Thormann M; Geipel S; Sowa JP; Barajas Ordonez F; Pech M; Omari J; Lemmer P
    Sci Rep; 2023 Oct; 13(1):17092. PubMed ID: 37816875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psoas Muscle Density in Combination with Model for End-Stage Liver Disease Score Can Improve Survival Predictability in Transjugular Intrahepatic Portosystemic Shunts.
    Shoreibah MG; Mahmoud K; Aboueldahab NA; Vande Lune P; Massoud M; Bae S; El Khudari H; Gunn AJ; Abdel Aal AK
    J Vasc Interv Radiol; 2019 Feb; 30(2):154-161. PubMed ID: 30717946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoas muscle index is not representative of skeletal muscle index for evaluating cancer sarcopenia.
    Pigneur F; Di Palma M; Raynard B; Guibal A; Cohen F; Daidj N; Aziza R; El Hajjam M; Louis G; Goldwasser F; Deluche E
    J Cachexia Sarcopenia Muscle; 2023 Aug; 14(4):1613-1620. PubMed ID: 37203274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical usefulness of psoas muscle thickness for the diagnosis of sarcopenia in patients with liver cirrhosis.
    Gu DH; Kim MY; Seo YS; Kim SG; Lee HA; Kim TH; Jung YK; Kandemir A; Kim JH; An H; Yim HJ; Yeon JE; Byun KS; Um SH
    Clin Mol Hepatol; 2018 Sep; 24(3):319-330. PubMed ID: 29706058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-transjugular Intrahepatic Portosystemic Shunt Hepatic Encephalopathy: Sarcopenia Adds Insult to Injury.
    Bhatia Kapoor P; Benjamin J; Tripathi H; Patidar Y; Maiwall R; Kumar G; Joshi YK; Sarin SK
    Turk J Gastroenterol; 2023 Apr; 34(4):406-412. PubMed ID: 36620928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of Improvement of Sarcopenia after Transjugular Intrahepatic Portosystemic Shunt Creation in Cirrhotic Patients.
    Huang S; Liu J; Cai J; Zhou C; Wang Y; Yang C; Li T; Chen Y; Ju S; Wang C; Yao W; Bai Y; Xiong B
    J Vasc Interv Radiol; 2023 Apr; 34(4):639-644. PubMed ID: 36586464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TIPS placement as the first-line therapy to prevent variceal rebleeding in patients with cirrhosis and sarcopenia.
    Xiong B; Yang C; Zhou C; Wu X; Huang S
    Eur J Radiol; 2023 Jan; 158():110630. PubMed ID: 36455336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cut-off values of skeletal muscle index and psoas muscle index at L3 vertebra level by computerized tomography to assess low muscle mass.
    Bahat G; Turkmen BO; Aliyev S; Catikkas NM; Bakir B; Karan MA
    Clin Nutr; 2021 Jun; 40(6):4360-4365. PubMed ID: 33516603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of different CT-based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis.
    Paternostro R; Lampichler K; Bardach C; Asenbaum U; Landler C; Bauer D; Mandorfer M; Schwarzer R; Trauner M; Reiberger T; Ferlitsch A
    Liver Int; 2019 Dec; 39(12):2374-2385. PubMed ID: 31421002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of transjugular intrahepatic portosystemic shunt on abdominal muscle mass in patients with decompensated cirrhosis.
    Wu CH; Ho MC; Kao JH; Ho CM; Su TH; Hsu SJ; Huang HY; Lin CY; Liang PC
    J Formos Med Assoc; 2023 Aug; 122(8):747-756. PubMed ID: 36868900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.